Medicine Invention Design, Inc Report issue

For profit Phase 3
Founded: Gaithersburg MD United States (2006)

Organization Overview

First Clinical Trial
2016
NCT01064466
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Dr. Han Xu | Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair | Han Xu, M.D., Ph.D., Sponsor-Investigator-Monitor, IRB Chair | IORG0007849 | IRB00009424 | Medicine Invention Design, Inc | Medicine Invention Design, Inc. - IORG0007849 | MIDINC Clinical Research Multiple Group Unit

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 7